

Prezista® (darunavir) – First-time generic

- On June 3, 2023, <u>Lupin launched AB-rated</u> generic versions of Janssen's <u>Prezista (darunavir)</u> 600 mg and 800 mg tablets.
 - In addition, Viatris and <u>Teva launched</u> AB-rated generic versions of Prezista 600 mg tablets.
 - Lupin's 800 mg tablets were granted 180-days of generic exclusivity.
 - Lupin, Viatris and Teva's 600 mg tablets were granted shared 180-days of generic exclusivity.
- Prezista co-administered with ritonavir, in combination with other antiretroviral agents, is approved for the treatment of human immunodeficiency virus infection in adult and pediatric patients 3 years of age and older.
- Prezista is also available as brand 75 mg and 150 mg tablets and 100 mg/mL oral suspension.
- According to IQVIA, annual sales for Prezista 600 mg and 800 mg tablets were approximately \$308 million in the 12 months ended March 2023.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.